Iradimed (IRMD) Cash & Equivalents (2013 - 2026)

Iradimed (IRMD) has reported Cash & Equivalents for 14 consecutive years, with $59.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 11.48% year-over-year to $59.1 million in Q2 2026; TTM through Jun 2026 was $59.1 million, a 11.48% increase from a year earlier, with the FY2025 full-year figure at $51.2 million, down 2.06% from the prior year.
• Cash & Equivalents was $59.1 million for Q2 2026 at Iradimed, up from $56.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $59.1 million in Q2 2026 and troughed at $42.8 million in Q1 2023.
• A 5-year average of $51.4 million and a median of $51.4 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slipped 15.91% in 2023 and increased 12.01% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $58.0 million in 2022, then dropped by 14.15% to $49.8 million in 2023, then grew by 4.97% to $52.2 million in 2024, then slipped by 2.06% to $51.2 million in 2025, then increased by 15.48% to $59.1 million in 2026.
• The last three Cash & Equivalents figures came in at $59.1 million (Q2 2026), $56.4 million (Q1 2026), and $51.2 million (Q4 2025), per Business Quant data.